Patent · US Active

Compositions and methods for inhibition of the JAK pathway

US8324200B2 · kind B2 · utility

19Cited by

8References

46Claims

0Family size

Assignee

Rigel Pharmaceuticals, Inc. · US

Inventors

Hui Li · Santa Clara, US
Thilo J. Heckrodt · San Francisco, US
Yan Chen · Sunnyvale, US
Darren McMurtrie · Daly City, US
Vanessa Taylor · San Francisco, US
Rajinder Singh · Belmont, US
Pingyu Ding · Foster City, US
Sambaiah Thota · Fremont, US
Rose Yen · San Francisco, US

Key dates

Filing date	Jan 22, 2010
Grant date	Dec 4, 2012
Priority date	—
Expiry date	Jun 11, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07F9/65583
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.